Zylox-Tonbridge has entered into a definitive agreement to acquire a Germany-based medical technology company, Optimed Medizinische Instrumente GmbH, in multiple stages to expand its global medical technology capabilities.

• Transaction structure: Zylox-Tonbridge has the option to acquire full equity interest in Optimed from its existing shareholders, subject to regulatory approvals and customary closing conditions.
• Product focus: Optimed develops and distributes medical devices for minimally invasive therapy, including venous stents supported by clinical evidence from studies such as STEVECO and sinus-Venous.
• Operational integration: The transaction is expected to create a unified platform across research and development, manufacturing, and commercialisation, with expanded manufacturing operations in Germany and integration of sales and service teams.

This summary is based on a news article published by BioSpectrum Asia.

Image for illustrative purposes only. Source: Canva.

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.